We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
MitoQ (Mitoquinol Mesylate)
A mitochondria-targeted antioxidant — CoQ10 conjugated to a triphenylphosphonium (TPP+) cation so it accumulates several-hundred-fold inside mitochondria. Sold OTC as a supplement. Its best human signal is improved endothelial/vascular function in older adults (one small RCT); several trials are null (Parkinson's, exercise adaptation), and almost all outcomes are surrogate/biomarker, not hard clinical endpoints.
What the evidence says
Most MitoQ studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 2010–2023 with a typical study size of 23 participants.
Based on 7 studies · 6 RCTs · 230 total participants
Confidence
ModerateBy outcome
MitoQ has an evidence score of 5/10 — moderate evidence based on 7 indexed studies. A mitochondria-targeted antioxidant — CoQ10 conjugated to a triphenylphosphonium (TPP+) cation so it accumulates several-hundred-fold inside mitochondria. Sold OTC as a supplement. Its best human signal is improved endothelial/vascular function in older adults (one small RCT); several trials are null (Parkinson's, exercise adaptation), and almost all outcomes are surrogate/biomarker, not hard clinical endpoints. Representative study: PMID 20568096.
The commonly studied dose of MitoQ is 10-20mg daily. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Explore: Best supplements for Vitality & LongevityBest supplements for Focus, Memory & MoodBest supplements for Athletic Performance
Last reviewed June 2026 · evidence from 7 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Earns a Moderate 5: a well-characterized mitochondria-targeting mechanism plus a small positive RCT for endothelial function in older adults and supportive vascular pilots, offset by a clearly null landmark Parkinson's trial, null exercise-adaptation data, and the fact that nearly every positive outcome is a surrogate biomarker (FMD, ALT) rather than a hard clinical or lifespan endpoint.
MitoQ is mitoquinol/mitoquinone mesylate — the antioxidant quinone of coenzyme Q10 chemically tethered to a lipophilic triphenylphosphonium (TPP+) cation.
The positive charge drives the molecule across the mitochondrial inner membrane, where it concentrates several-hundred-fold relative to ordinary CoQ10 and is recycled by the respiratory chain back to its active ubiquinol form.
The rationale is that excess mitochondrial reactive-oxygen-species (ROS) production drives age-related vascular dysfunction, so a mitochondria-targeted antioxidant should improve function where untargeted antioxidants fail.
The honest read of the human evidence: the single best signal is a small crossover RCT in healthy older adults (Rossman 2018, Hypertension) where 6 weeks of 20 mg/day raised brachial-artery flow-mediated dilation (a surrogate marker of endothelial function) by ~42%.
Smaller pilot RCTs echo acute or short-term vascular improvements in peripheral artery disease and chronic kidney disease, and a phase-II hepatitis-C trial lowered liver aminotransferases (ALT) without changing viral load.
Against that, the largest and most rigorous clinical trial — the PROTECT study in newly-diagnosed Parkinson's disease (128 patients) — found NO effect on disease progression, and a controlled exercise-training study found MitoQ neither helped nor hurt aerobic adaptations.
So the evidence is genuinely mixed: a plausible, well-characterized mechanism and a few positive surrogate-marker RCTs in vascular function, set against null disease-modifying trials and an absence of any hard clinical-outcome or lifespan data in humans.
It is generally well tolerated at studied doses (10-20 mg/day), making it a reasonable, modest-evidence option for those targeting vascular/mitochondrial support rather than a proven therapy.
A lipophilic triphenylphosphonium cation drives accumulation several-hundred-fold inside mitochondria.
Neutralizes mitochondrial reactive oxygen species (ROS) at their source, regenerated by the respiratory chain.
Reducing mitochondrial ROS improves vascular endothelial function in aging arteries.
How MitoQ works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
10-20mg daily
Can be taken without food
| Form | Type |
|---|---|
| 💊Oral capsule (mitoquinol mesylate, 10-20 mg) | Recommended |
| 💊Ordinary CoQ10 / ubiquinol (untargeted, much cheaper, different evidence base) | Alternative |
MitoQ is distinct from regular CoQ10: the TPP+ cation concentrates it inside mitochondria. The human evidence base is its own (small vascular RCTs), not transferable from CoQ10 trials.
Minimum: 6 weeks
Optimal: 12 weeks
Cycling: Not required
Note: Once daily in the morning, typically on an empty stomach. Trials dosed 20 mg/day for vascular outcomes.
Dose-response data unavailable. The current published research for MitoQ does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Raised flow-mediated dilation (a surrogate marker of vascular function) in healthy older adults in a small RCT; echoed in PAD and CKD pilots.
Reduced serum ALT/AST in a phase-II hepatitis-C trial, suggesting less hepatic necroinflammation — without changing viral load.
The PROTECT RCT (128 patients) found MitoQ did NOT slow Parkinson's disease progression on any measure.
Did not enhance (or impair) endurance-training adaptations — VO2max, muscle mitochondrial capacity — in young healthy men.
Insufficient safety data; avoid unless directed by a clinician.
The main RCT population (60-79 yr); 20 mg/day was well tolerated over 6 weeks.
Studied in small hepatitis-C and CKD pilots and tolerated, but only short-term; involve the treating clinician.
Possible additive vascular/BP effects given the endothelial-function mechanism; monitor.
As with other CoQ10-related compounds, theoretical interaction with warfarin; monitor INR.
Tip: Generally well tolerated in trials; take with a small amount of food if it occurs.
Tip: Usually transient; reduce dose if persistent.
MitoQ is a mitochondria-targeted CoQ10 derivative; the two share an antioxidant/electron-transport rationale.
Overlapping mitochondrial-support rationale — largely redundant rather than additive.
Urolithin A promotes mitophagy (clearing damaged mitochondria); MitoQ reduces mitochondrial ROS in those that remain.
Complementary mitochondrial-quality support through distinct mechanisms.
NMN raises NAD+ to support mitochondrial function; MitoQ targets mitochondrial oxidative stress.
Complementary mitochondrial and cellular-energy support.
The best time to take MitoQ is in the morning. It can be taken on an empty stomach. Most human trials dosed MitoQ once daily at 20 mg in the morning on an empty stomach (the manufacturer recommends taking it ~30-60 min before food).
MitoQ is generally well-tolerated and considered safe for most healthy adults at recommended doses. The most commonly reported side effects are GI upset / abdominal discomfort, headache. Use caution if any of these apply to you: None established at studied doses; consult a clinician if pregnant, nursing, or on the medications below.
A vitamin B3 precursor that reliably raises cellular NAD+ levels and is well tolerated — but human trials have so far shown mostly null or mixed results on the functional outcomes (muscle, metabolism, blood pressure, cognition) that elevation is meant to drive.
Tap node to isolate • Pinch to zoom • Tap edge for research